Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from KRBP

3 Low-Rated POWR Stocks to Sell Immediately

The economic situation appears to be grim, with higher interest rates and the recent turmoil in the financial system causing sluggish growth in the first three months of this year. Hence, it could be wise to avoid struggling stocks Pliant Therapeutics (PLRX), Local Bounti (LOCL), and Kiromic BioPharma (KRBP). These…

StockNews.com · Apr 28, 2023

Kiromic BioPharma's Prioritizes New Gamma Delta T-Cell Product Candidate

Kiromic BioPharma's Prioritizes New Gamma Delta T-Cell Product Candidate

Kiromic BioPharma Inc (NASDAQ:KRBP) has announced a strategic pipeline shift to prioritize its allogeneic, non-engineered off-the-shelf product candidate, Deltacel/KB-GDT. Kiromic expects to submit its first new investigational new drug (IND) application to the FDA in 2H of 2022. The IND will seek to evaluate Deltacel in combination with a standard antitumor modality, with…

Benzinga · Jun 21, 2022

Why Kiromic Biopharma Shares Are Skyrocketing Today

Why Kiromic Biopharma Shares Are Skyrocketing Today

Kiromic Biopharma Inc (NASDAQ: KRBP) shares are trading higher by 78.5% at $0.50 after the company entered a Sponsored Research Agreement (SRA) under which in vivo preclinical data will be generated from Kiromic's Gamma Delta T cell allogeneic therapies.

Benzinga · Jun 7, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

1

Coverage From

Organisations

US Federal Reserve

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play